TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01802515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine, low dose
Description: The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine, high dose
Description: The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
Study: NCT01002495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Endocardial injections on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Endocardial injections on Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Description: Endocardial injections on Day 0.
Study: NCT00154193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
Study: NCT04909294

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiotherapy with Linac MRI
Description: 38 Gy in 4 fractions of 9.5 Gy over the entire prostate,~+/- 2 Gy in 4 fractions of 0.5 Gy as an integrated boost on the index tumor if it is visible on diagnostic multiparametric MRI (PIRADS-V2 score 4 or 5) and on planning MRI performed on Linac MRI.
Study: NCT01292525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group.
Study: NCT02251067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VPI-2690B low dose
Description: Comparison of different doses of study drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VPI-2690B medium dose
Description: Comparison of different doses of study drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match VPI-2690B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VPI-2690B high dose
Description: Comparison of different doses of study drug
Study: NCT01752075

Intervention type: DRUG
Intervention: Revlimid
Description: The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
Study: NCT04324268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study: NCT03582189

Intervention type: OTHER
Intervention: MRI
Description: Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
Study: NCT04324268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lirentelimab (AK002)
Description: Lirentelimab (AK002) is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03403855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rocket® IPC- Long External Length
Description: Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rocket® IPC- Short External Length
Description: Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
Study: NCT04319640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for insomnia
Description: CBT-I for children with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 5 weekly modules.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation for ASD
Description: psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation for ASD
Description: psychoeducation contains information about ASD, The treatment consists of 5 weekly modules.
Study: NCT03998891

Intervention type: OTHER
Intervention: restricted dietary salt intake
Description: These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
Study: NCT02579902

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: 50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
Study: NCT01085656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXi4503
Description: Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent.
Study: NCT03385525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Administered as specified in the treatment arm
Study: NCT02562027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30
Description: * 30 quality of life questions for the participant to answer~* The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~* The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13
Description: * 13 quality of life questions for the participant to answer~* The answers range from 1 (Not at All) to 4 (Very Much)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council
Description: * Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQ-5D
Description: * 5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~* The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies Depression Scale
Description: * 20 quality of life questions for the participant to answer~* Answers range from Rarely or none of the time to Most or all of the time~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Outcomes Study Social Support Survey
Description: * 19 quality of life questions for the participant to answer~* Answers from from 1 (None of the time) to 5 (All of the time)~* Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment
Study: NCT00323310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadobenate dimeglumine
Description: A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
Study: NCT02078661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PG101
Description: A topical gel containing either 1% or 0.25% PG101 active.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PG101
Description: A topical gel containing either 1% or 0.25% PG101 active.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PG101
Description: A topical gel containing either 1% or 0.25% PG101 active.
Study: NCT02896192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Once daily SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily SC injection
Study: NCT02079519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was provided as a concentrate in vials.
Study: NCT00645515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
Study: NCT00062647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin, nafcillin, oxacillin, or cloxacillin
Description: Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
Study: NCT00033371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Given 400 mg PO twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given 400 mg PO twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO to match DFMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Description: Given PO at 0.5 gm/m\^2/day rounded down to the nearest 250 mg dose (BSA of \< 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of \> 2.6 = 1,250 mg/day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study: NCT02883426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
Description: Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
Description: Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
Description: Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)
Description: Approximately 10\^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H3N2v inactivated subvirion influenza vaccine
Description: 15 μg; administered intramuscularly

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by nasal spray

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by nasal spray

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by nasal spray
Study: NCT00601679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NT-proBNP guided care
Description: knowledge of NT-proBNP results
Study: NCT01847690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Cortef 5 mg tablets per os, 2x5 mg, one day, one time
Study: NCT03290794

Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Intravitreal Aflibercept as prescribed by the treating Physician
Study: NCT01512472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: degarelix
Description: Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
Study: NCT05906667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sharing History through Active Reminiscence and Photo-imagery (SHARP)
Description: Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks
Study: NCT01444872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRV120027
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV infusion
Study: NCT01475318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 200 mg mifepristone on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 10mg PO on day 1, day 2, and day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: misoprostol 800mcg PV on day 3
Study: NCT03446001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 16 mg/day
Description: Oral TRx0237 4-mg tablets administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRx0237 8 mg/day
Description: Oral TRx0237 4-mg tablet administered twice daily
Study: NCT03012542

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet 1
Description: Diet controlled in amount and source of carbohydrates or fiber containing foods.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet 2
Description: Diet controlled in amount and source of carbohydrates or fiber containing foods.
Study: NCT02508519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: An acupuncture needle insertion according to zonal or balance method.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: An acupuncture needle insertion according to zonal or balance method.
Study: NCT00524043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 1.5 mg tablet once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone ER
Description: 6 mg tablet once daily for 6 weeks
Study: NCT01335490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel
Description: The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel
Description: The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
Study: NCT01499797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The CareWell programme
Description: The CareWell programme contains the following components:~* multidisciplinary primary care teams~* working with proactive care plans integrating cure, care and welfare~* advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~* medication review~* case-management~* guidelines for consultation of in-hospital geriatric experts~* guidelines for transfers from primary care to home-based facilities and hospital and back~* practice guidelines for management of common geriatric conditions
Study: NCT00513994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin
Description: MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
Study: NCT03175016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eluting-bead
Description: The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
Study: NCT04776915

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Hysterosalpingography
Description: Ultrasound and Hysterosalpingography

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and Hysterosalpingography
Description: Ultrasound and Hysterosalpingography